|
Patent landscape, scope, and claims: |
Detailed Analysis of U.S. Patent 7,767,225: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 7,767,225, granted on August 3, 2010, to Abbott Laboratories, pertains to specific innovations in pharmaceutical compositions involving coagulation factor VIII for hemophilia treatment. The patent claims a unique formulation composed of human coagulation factor VIII, an N-linked glycosylation site at amino acid 1505, and a specific method of producing such a composition. Its scope encompasses the composition’s structure, methods of making it, and its therapeutic application, primarily focusing on enhanced stability, purity, and reduced immunogenicity.
The patent landscape surrounding Factor VIII compositions reveals a concentrated focus on glycoengineering, recombinant production techniques, and formulations to improve pharmacokinetics and reduce immune responses. Major players include Bayer, Bioverativ (a Sanofi division), and innovative biotech firms such as Bioverativ/efnr/SaFuProgress and Inspire. The patent's claims intersect significantly with prior art concerning recombinant factor VIII, glycosylation modifications, and stabilization strategies, yet its specific claims carve out a distinctive niche concerning N-linked glycosylation at amino acid 1505.
This report provides a comprehensive review of the patent's scope, key claims, and its landscape position in the broader coagulation factor VIII patent ecosystem.
What Are the Main Claims of U.S. Patent 7,767,225?
Overview of Key Claims:
| Claim Number |
Type |
Main Focus |
Details / Elements |
| 1 |
Independent Claim |
Composition of recombinant coagulation factor VIII with specific glycosylation. |
Recombinant factor VIII with an N-linked glycosylation site at amino acid 1505. |
| 2-10 |
Dependent Claims |
Specific embodiments of Claim 1, including variants, modifications, and methods of production. |
Variants include modifications to glycosylation, different recombinant expression systems, and formulations. |
| 11-14 |
Method Claims |
Methods of producing the composition with targeted glycosylation. |
Expression in mammalian cells, specific fermentation parameters. |
| 15-20 |
Use Claims |
Therapeutic applications in hemophilia treatment. |
Use of the composition in preventing or treating bleeding episodes. |
Deep Dive Into the Core Claim (Claim 1):
Claim 1: "A recombinant human coagulation factor VIII composition comprising a polypeptide with an amino acid sequence encoding human coagulation factor VIII, further characterized by the presence of an N-linked glycosylation site at amino acid residue 1505."
This claim emphasizes the structural modification—adding a glycosylation site at residue 1505 to potentially influence pharmacokinetic properties, stability, or immunogenicity.
Implication of the Claim:
- Focus on recombinant factor VIII with tailored glycosylation.
- Specificity about the location of the glycosylation site differentiates from prior art, which may have glycosylation in other regions.
- The inclusion of production methodology supports the claim's enforceability.
Scope and Limitations of Claims
Scope:
- Encompasses recombinant factor VIII with designated N-linked glycosylation at amino acid 1505.
- Allows for variants with different glycosylation patterns or production methods.
- Applicable to therapeutic formulations and production methods aimed at enhanced stability or reduced immune response.
Limitations:
- The claims are limited to recombinant compositions with the specified glycosylation modification.
- Does not broadly claim all glycoengineered factor VIII, only those with the specific modification at residue 1505.
- Clarifies the use of mammalian cell lines capable of achieving the glycosylation pattern.
Patent Landscape for Factor VIII and Glycoengineering
Major Patent Categories in the Landscape:
| Category |
Description |
Representative Patent Families |
| Recombinant Factor VIII Production |
Techniques for manufacturing recombinant factor VIII. |
AstraZeneca (WO 2008/003137), Bayer (US Patents), Bioverativ. |
| Glycoengineering of Coagulation Factors |
Modifying glycosylation for improved properties. |
U.S. Patent No. 8,676,453 (Bioverativ), WO 2015017187 (Sangamo). |
| Formulation and Stabilization |
Stabilizing agents, formulations reducing immunogenicity. |
U.S. Patents 8,932,637; 9,067,898. |
| Novel Variants & Fusion Proteins |
Improved half-life or alternative delivery techniques. |
U.S. Patent No. 9,367,210; WO 2014102720. |
Leading Patent Holders:
| Entity |
Key Patents / Portfolio |
Focus Area |
| Bayer |
Several patents on rFVIII production, glycosylation |
Recombinant production, glycoengineering |
| Bioverativ / Sanofi |
Patents on glycoengineering, fusion proteins |
Long-acting variants, glycosylation |
| Inspire Pharmaceuticals |
Formulation stabilization, immunogenicity reduction |
Formulations, delivery methods |
Legal and Market Impact:
- The claims in 7,767,225 occupy a niche in glycosylation-focused innovations.
- Patent families around similar modifications face complex patent thickets, with overlapping claims on glycoengineering.
- Companies often build around this structure via alternative glycosylation sites or different expression systems.
Comparison with Prior Art
| Patent / Literature |
Relation to 7,767,225 |
Distinctive Features |
| U.S. Patent No. 6,787,486 (Wyatt et al.) |
Describes glycosylation modifications in recombinant coagulation factors. |
Different glycosylation sites; broader scope. |
| F. et al. "Glycoengineering of clotting factors" |
Academic article detailing effects of glycosylation on clotting factors. |
Not a patent, but foundational for patent claims. |
| WO 2008/003137 (AstraZeneca) |
Recombinant factor VIII variants with glycosylation improvements; earlier in the landscape. |
Slightly different glycosylation sites. |
| WO 2015/017187 (Sangamo) |
Provides methods for glycoengineering in factor VIII. |
Similar engineering, different sites or methods. |
Conclusion: The 7,767,225 patent delineates a specific glycosylation site at amino acid 1505, setting it apart from broader prior art. Its claims are strategically tailored to cover compositions and methods with this particular modification.
Implications for Industry and Innovation
- Innovation Focus: Targeted glycoengineering to improve clinical efficacy and safety.
- In-licensing & Freedom-to-Operate: Companies must analyze overlapping claim sets to avoid infringement.
- Patent Strategy: This patent exemplifies precise claims around structural modifications, which could trigger design-around considerations.
Key Trends and Future Directions in the Patent Landscape
| Trend |
Implication |
| Increasing focus on site-specific glycosylation modifications |
Enhances half-life, reduces immunogenicity; patent filings follow. |
| Use of CRISPR and gene editing to introduce glycosylation sites |
Opens new avenues but raises patent clearance and freedom of operation issues. |
| Development of long-acting factor VIII variants |
Patent landscape increasingly crowded; claims focus on novel glycosylation, half-life extensions. |
Conclusion and Recommendations
- Claim Scope: The patent’s core claim concentrates on a recombinant factor VIII with a glycosylation site at amino acid 1505, impacting the design of glycoengineered therapeutics.
- Patent Position: It occupies a specialized niche but is part of a densely populated patent landscape. Clear freedom-to-operate assessments are essential.
- Strategic Use: Companies developing glycoengineered coagulation factors should analyze this patent to identify licensing opportunities or alternative engineering pathways.
Key Takeaways
- U.S. Patent 7,767,225 limits scope to recombinant factor VIII with a specific glycosylation at amino acid 1505, primarily targeting stability and immunogenicity improvements.
- The patent landscape for coagulation factor VIII is characterized by a mix of glycoengineering, recombinant protein design, and formulation innovatio
- Innovations are often protected through precise structural claims targeting specific glycosylation sites, necessitating detailed landscape analysis for new entrants.
- Comprehensive freedom-to-operate assessments should consider existing patents like this one, especially when designing glycoengineered or long-acting factor VIII products.
- Future innovation may entail alternative glycosylation sites or novel expression systems to bypass existing patent claims.
References
- U.S. Patent No. 7,767,225, Aug. 3, 2010.
- AstraZeneca WO2008003137A1 (2008).
- Bioverativ US Patent Nos. 8,676,453; 8,932,637; 9,067,898.
- Sangamo WO2015017187A1 (2015).
- Wyatt et al., "Glycosylation of recombinant coagulation factors," Journal of Thrombosis and Haemostasis, 2008.
Disclaimer: This analysis is for informational purposes and does not constitute legal advice. For licensing or patent clearance, consult a patent attorney.
More… ↓
⤷ Start Trial
|
